A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

March 26, 2025

Primary Completion Date

April 22, 2027

Study Completion Date

November 28, 2029

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

DRUG

FDC fianlimab+cemiplimab

Fixed-Dose Combination (FDC) Administered per the protocol

DRUG

Cemiplimab

Administered per the protocol

DRUG

Placebo

Administered per the protocol

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY